ACCESS Newswire

Zenith Energy Ltd.

Share
Update on Italian Energy Production Portfolio

CALGARY, AB / ACCESSWIRE / March 12, 2024 / Zenith Energy Ltd. ("Zenith" or the "Company") (LSE:ZEN)(OSE:ZENA)(OTCQB:ZENAF), the listed international energy production and development company, is pleased to announce the full completion of an acquisition in Italy, as well as providing an update on its Italian energy production portfolio.

Acquisition of additional stake in Sant'Andrea natural gas production concession ("Sant'Andrea")

The Company is pleased to announce that it has acquired, and received the necessary final regulatory approvals, for the acquisition of an additional 10% interest in Sant'Andrea (the "Acquisition") from Petrorep Italiana S.R.L. ("Petrorep").

Following completion of the Acquisition, Zenith's 40% interest in Sant'Andrea has increased to 50%.

As previously announced, the Company plans to reactivate the S. Antonio-1 well located in Sant'Andrea, with an expected initial production rate of approximately 1,500 cubic metres of natural gas per day.

Under the terms of the acquisition, Petrorep has paid Zenith's Italian subsidiary the amount of EUR 248,000 (approximately GBP 212,000 or NOK 2,850,000) to cover its share of future plugging and abandonment costs calculated pro rata based on its participation in Sant'Andrea.

The Company is confident that production from Sant'Andrea will commence in October 2024.

Zenith's partners in Sant'Andrea have communicated that they do not intend to fund the costs associated with its reactivation. Zenith will therefore receive full entitlement to the production revenue to be received from Sant'Andrea, as well as bearing the full costs associated with the reactivation of production, estimated in the amount of EUR 20,000.

Italian Electricity Production - Torrente Cigno Concession ("Torrente Cigno")

The Company continues to generate electricity at the Torrente Cigno with an average monthly production of approximately 950 megawatt hours ("MWh").

Electricity prices averaged approximately EUR 96 per MWh during January 2024 and averaged approximately EUR 84 during the month of February 2024, resulting in cumulative net revenues of approximately EUR 171,000 for the period.

Zenith's current net production costs remain fixed at approximately EUR 35,000 per month.

Andrea Cattaneo, Chief Executive Officer, commented:

"We are pleased to have increased our participation in Sant'Andrea which we hope to bring to production later this year, creating an additional revenue stream for the Company.

I am pleased to report that the Company is currently evaluating a potentially significant additional acquisition in Italy, and I look forward to providing updates in due course if negotiations prove successful."

Further Information:

Zenith Energy Ltd
Andrea Cattaneo, Chief Executive Officer

Tel: +1 (587) 315 1279
E: info@zenithenergy.ca

Allenby Capital Limited - Financial Adviser
Nick Harriss
Daniel Dearden-Williams

Tel: + 44 (0) 203 328 5656

Notes to Editors:

Zenith Energy Ltd. is a revenue generating, independent energy company with energy production, exploration and development assets in North Africa, the US and Europe. The Company is listed on the London Stock Exchange Main Market (LSE:ZEN), the Euronext Growth of the Oslo Stock Exchange (OSE:ZENA) and the Venture Market of the OTCQB (OTCQB:ZENAF).

Zenith's strategic focus is on pursuing development opportunities through the development of proven revenue generating energy production assets, as well as low-risk exploration activities in assets with existing production.

For more information, please visit: www.zenithenergy.ca

Twitter: @zenithenergyltd

LinkedIn: https://bit.ly/3A5PRJb

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

SOURCE: Zenith Energy Ltd.



View the original press release on accesswire.com

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release

Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release

Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen

Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release

SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan

Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release

On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI

PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release

MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye